Gary Hattersley serves as the Chief Scientific Officer at Nuvation Bio, leading the companys research and development efforts in oncology. His career spans over two decades in the biotech industry, with significant experience in drug discovery and translational science. He holds a PhD from St. Georges Hospital Medical School, London.
He played a pivotal role in the development and 2017 FDA approval of TYMLOS®, a key treatment for osteoporosis, during his 15-year tenure at Radius Health.
Read the full overview →Explore more public profiles from related professionals.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.